Anti-TrkB agonist antibodies binding to D1 domain of TrkB
US12037400B2 · kind B2 · utility
0Cited by
20References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2021 |
| Grant date | Jul 16, 2024 |
| Priority date | — |
| Expiry date | Nov 23, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.